Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

C-RAD, Audiocast, Q2'25

By Inderes7/18/2025, 9:00 AM
C-Rad

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Cecilia de Leeuw
00:02 - 06:22

Welcome to our Q2 presentation, and thank you for joining us today in the middle of the Swedish summer. We have concluded a busy quarter with high activity in all markets, achieving increased order intake and securing deals despite market uncertainty. As many of you know, the foundation of our offering is the demand and need for safer cancer treatments with a focus on the patient's quality of life. And it's also about increasing efficiency in the customers' clinics. And we are on a journey. We are building an even stronger company, working hard on our financial strengths so that we can access both established and untapped markets globally with our world-leading products and services. So now let's take a look at the Q2 performance and the key takeaways. Q2 was indeed a busy quarter, and we are taking steps towards our financial targets. And I am pleased that the hard work done by the team driving marketing activities, participating in trade shows, and organizing reference site visits, which is common in the final phase of the customer buying process, is paying off. We took a number of larger deals in both the US and EMEA in the second quarter. Our order intake grew by 11% in constant currencies. The main contribution came from EMEA and the Americas, and we ended the quarter with a strong order backlog of 735 million SEK. And when looking at the backlog, approximately half of the order backlog consists of products and the other half of service contracts, which are typically 3 to 5 years. And this does, of course, provide good recurring revenue. Invoiced at the start of each quarter, revenue year on year declined by 13% in constant currencies, and the main reason is a softer order intake during 2024. And it's also worth noting that Q2 last year was boosted by approximately 20 million SEK of China deliveries due to the product registration approval, and the weaker top line had a direct impact on EBIT. And we came in with a moderate 8 million SEK. However, we have a stable gross margin, and Linda will share more soon. Our EBIT margin in the quarter was 8%. We are improving operational efficiency step by step and have reduced OpEx by 10% compared to Q2 last year. And the focus on cost efficiency is now part of our DNA, which means that we are continuously driving both cost control and implementing measures to streamline operations. And that said, we have more work to do. So let's look into the regional performance in the quarter. And I'll start off with the Americas. And our long-term focus is to strengthen our position in the US market. And we made good progress this quarter despite uncertainty in the US market. And this is mainly due to tariffs. The two large orders in the quarter that we are showing here on the slide represent different aspects of our untapped opportunity. The product order to a prominent Proton facility is for bunkers in their newly built satellite facility, and I am delighted that this existing customer decided to expand their footprint with us. The other large order is a pure service contract with a renowned cancer center on the East Coast. And this is a renewal which is important to us, and it's a clear indication of the strength of our offering and our focus on customer retention. Order intake for the Americas increased by 11% to 31 million in Q2, and revenue grew by 26% in the quarter. Moving over to EMEA, the hard work by the team is paying off in the quarter. We have good momentum, and we were rewarded with an 8.5 million SEK strategic multi-site product and services contract in France with the leading private care provider, Ronce Santé Group. And we are motivated by this, as France is a market where we are coming from a challenger position. We can also see signs of recovery in the important German market, and I am pleased that we received a 9 million SEK product and service contract from one of the most important healthcare providers in the dynamic Stuttgart region in southern Germany. Order intake increased 47% to 46 million, and revenue in EMEA was down 11% to 43 million. Still impacted by a lower order intake during last year. And finally, APAC had a softer second quarter. Q2 last year was fueled by a vital boost. Order intake benefited from the earlier Japanese market launch at the end of 2023. However, APAC is still our largest market, and there is untapped demand in advanced markets as well as the large developing markets in the region. We have a healthy market mix and see an increasing uptake of SGRT, and it's starting to become a given in the clinical workflow. Order intake declined 15% to 58 million, and revenue in APAC decreased by 34% to 44 million in Q2. And as I mentioned earlier, it's impacted by strong China deliveries last year. And if we adjust for these deliveries, APAC had a 1% growth in constant currencies. And with that, over to you, Linda. For a closer look at the financials.

Linda Frölén
06:23 - 10:32

Thank you, Cecilia. So I will take you through some of the main financials for the second quarter. As Cecilia has already explained order intake and revenue. I will not go into that again but rather focus on gross margin, cost levels, earnings, and cash flow. Gross profit for the quarter was 70 million, compared to 88 million a year ago. The decrease in gross profit follows the decrease in revenue year on year, as we had 20 million SEK in high-margin proton revenues from the long-awaited product registration approval in China last year. The gross margin for the quarter was 67% versus 68% last year, and the current levels are in line with what we have had in previous quarters and within the range of what we would have expected. The decrease in the gross margin year on year is explained by the high amount of proton revenue last year, which was partly compensated by a higher share of service revenue in this quarter. We had no proton revenues in this quarter. Looking at our main operating expenses, you see to the left of this slide that they decreased by 10% year on year, from 68 million last year to 61 million in this quarter. The decrease is mainly related to lower external expenses, as we have gradually replaced external consultants with our own employees. To the right of this slide. You see, quarter on quarter opex is up 9% from 56 million in Q1 to 61 million in this quarter. The increase is mainly related to the payout of sales commissions from earlier quarters that were not fully accounted for. The increase is also related to lower personnel expenses in Q1 due to holidays. We are monitoring our cost levels closely, and we are happy to see that our efficiency measures are showing results. Our yearly opex levels are now down by 31 million from the peak in Q3 last year, as we have now reached a more stable level. EBIT for the second quarter was 8 million compared to 18 million a year ago. The decrease in EBIT for this quarter is fully explained by the lower revenue, as both gross margin and OPEX are in line with our expectations. I can also mention that unrealized currency effects in this quarter were only minor. Our increased focus on smart spending is moving us in the right direction, and looking back a few quarters, Seerad shows continuously improved earnings and increased profitability over time. With this development as a foundation, we are well-equipped to continue to grow, as we believe we can increase the EBIT margin even more over time. According to our medium-term financial targets, we remain committed to our goals even if we may experience short-term deviations. Our cash balances decreased by 3 million during the quarter and stood at 158 million at quarter end, compared to 161 million at the beginning of the quarter. Cash flow from working capital was -8 million, which is a significant improvement from last year. But it is still on the negative side. The increase in working capital is related to accounts receivables, as a large number of old orders were invoiced late in the second quarter. A few orders on our balance sheet that have been awaiting final acceptance tests have been paid during the quarter, and many have also been invoiced after completed final acceptance tests. Some of these are expected to be paid during Q3. Last but not least, I would like to remind you that Seerad is a company with a strong balance sheet and no long-term debt. And with that, I will hand over back to Cecilia for some closing comments.

Cecilia de Leeuw
10:33 - 13:50

Thank you, Linda, and I'd like to summarize the quarter by highlighting the increased order intake generated by high market activity. In addition, I want to remind you of our financial targets for the medium term that were announced last quarter. And therefore, I'd like to conclude by taking you through our Q2 progress on our journey towards our financial targets, strategy, and priorities. So let me take you through this slide left to right. First, our strategic goal is to grow sales and expand market reach globally. Seerad already today has a global reach. And we are expanding step by step to grow our sales. And our growth target means that we will further penetrate markets, capturing unmet demand. And for Q2, order intake grew by 11% in constant currencies. And as I already mentioned, this is mainly driven by the Americas and EMEA. And this aligns with our strategic ambition to grow in the US and focus on EMEA advanced markets, where we had significant wins this quarter. Secondly, our strategic ambition is to ensure that we have world-leading products. We have a highly competitive portfolio and will continue to invest and innovate in the offering and in new complementing solutions. And in this quarter, we introduced a new and improved gating solution. And this integrated gating interface is developed together with one of our leading industry partners and integrated with the linear accelerator. And thirdly, there is truly untapped market potential. And as is the standard of care in many markets. And still, it's early days, and there are many systems without these capabilities. And hence, we see a potential to retrofit existing linear accelerators and proton machines. And we also see a great opportunity to grow services as our installed base of systems is expanding. And this is another priority for us. And services are not only important for sales and happy customers, but they also generate recurring revenue and support our profitability. And for Q2, order intake for services grew by 86% in constant currencies compared to Q2 last year. And finally, we are steering towards our financial targets. And our company has good financial stability and is building a resilient organization, supporting scalability. And it's resilient from a market perspective, building a more mature company that supports growth. And for Q2, we have further trimmed down our OpEx by 10%. And this is mainly achieved by replacing consultants, as you heard from Linda. Within administration and also within service. And we are taking steps towards our financial targets. And with that, over to you, Moderator for Q&A.

Operator
13:54 - 14:18

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. If you are listening to the presentation through the webcast, you can ask a question by clicking the raised hand symbol. The next question comes from Oscar Bergman from Redeye. Please go ahead.

Oscar Bergman
14:21 - 14:48

Hello, Cecilia and Linda. I have a few questions that are not really related to the quarter, but more so on the general level. Uh, the first one is about competition for service scanning. Could you just briefly elaborate on the main value propositions? And also, are your selling activities dependent on any cyclical buying patterns among your customers?

Cecilia de Leeuw
14:51 - 16:15

So, if I start this off. So, uh, when it comes to the value proposition, it's, um, both in terms of targeting only the healthy tissue on the patient, which has societal value, and also, of course, patient value. Uh, the other point is, of course, the efficiencies in the clinic. And this is a very minor investment for the clinic. So, we say it's typically only about 5% of the total investment. So for a lot of return, it's a minor investment. And, in terms of how these cycles work, this is not typically a cycle as such. Uh, but it's something that we see happening over the years. Uh, we sometimes see higher purchases at the end of the year, depending on the budgets for the hospital. But that, uh, that depends. And, you know, it's also worth saying that this is a highly regulated market. So, when it comes to competition, it's not such an easy market to enter because you have to have registration in each and every market.

Oscar Bergman
16:17 - 16:22

Sure. And how do you typically compete? Do you compete on pricing, or is it more on functionality?

Cecilia de Leeuw
16:24 - 16:42

Uh, I would say that we always try to compete on functionality and can probably say that we have a lot of uniqueness here. Uh, however, it is also true that sometimes there is a market price that we have to manage. So I would say it's a combination.

Oscar Bergman
16:44 - 17:00

So, so if I, if I start, uh, start this off. And if you look at the market, can you see any estimates on what percentages of the machines are equipped with this type of technology and how you expect this to change in the coming five years? If there are any big trends, they are moving this in the right direction.

Cecilia de Leeuw
17:01 - 17:50

And, as I mentioned earlier in the presentation, we see that it's increasingly becoming the standard of care. Uh, and in advanced markets, let's say Germany, for example, there is a slightly higher percentage compared to developing markets. You have markets that so far don't have any STDs. So, so it's, uh, it's a big difference. Uh, but the standards that came out at the end of 2022, of course, are supportive. Uh, so, uh, but if we look at the attachment rate in different markets, uh, in the US, for example, it's slightly higher, it's more, uh, north of 40%, and in developing markets, it could be, you know, from zero and up.

Oscar Bergman
17:51 - 17:59

So, so if I, if I start, uh, start this off. And I guess it's fair to assume that for the proton centers, you have an even higher attachment rate than for photon.

Cecilia de Leeuw
18:01 - 18:37

It varies there as well. There are a lot of opportunities. And if you look at the opportunity, sometimes it's part of a newly built bunker. Sometimes we retrofit existing proton machines. But also there, as an example, we have a client at the Miami Cancer Center in Florida, USA. And there, they have CBCT on all machines, both proton and photon. So that's, of course, a very strong reference for us.

Oscar Bergman
18:38 - 18:52

It's a lot of opportunities. It's a lot of opportunities. And just one final question from me. Maybe this is mentioned somewhere in the report or on your web page. But, uh, can you, uh, say how many art centers worldwide you are actually installed at today?

Cecilia de Leeuw
18:54 - 19:02

We don't typically disclose that today, but we are in more than 50 countries worldwide.

Oscar Bergman
19:03 - 19:07

It's a lot of opportunities. But are you looking into providing such details going forward?

Cecilia de Leeuw
19:08 - 19:09

Yeah, we'll look into that.

Oscar Bergman
19:11 - 19:12

It's a lot of opportunities. Thank you.

Cecilia de Leeuw
19:13 - 19:13

It's a lot of opportunities.

Operator
19:18 - 19:23

The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
19:26 - 19:49

It's a lot of opportunities. And good morning, Linda. Thank you for taking my questions. I have three, please. Uh, the first is regarding the strong order intake in the quarter. Um, do you expect the good momentum in EMEA to continue in the second half of the year? And how do you view your chances of winning more significant product orders in the US in the near term? It's a lot of opportunities.

Cecilia de Leeuw
19:52 - 20:17

So when it comes to EMEA, as I mentioned earlier, it's nice to see that EMEA is starting to pick up again. Uh, of course, it's too early to say. And I.

Christian Lee
20:17 - 20:17

Think.

Cecilia de Leeuw
20:17 - 20:18

You can.

Christian Lee
20:18 - 20:18

Yes.

Cecilia de Leeuw
20:18 - 20:20

Can you repeat the US question?

Christian Lee
20:22 - 20:27

Yes. What are your chances of winning more significant product orders in the US?

Cecilia de Leeuw
20:38 - 20:41

Yes. You have to take it one more time, Christiane. Sorry.

Christian Lee
20:43 - 20:58

Yes. Sorry about the bad line here. Um, I was wondering if you could share your view on your chances of winning more significant product orders in the US in the near term, as the majority have been service contracts.

Cecilia de Leeuw
20:59 - 21:52

Right. Uh, no, that's, uh, it's, it's, uh, it's, um, you know, to start off, you know, we are also very happy with the, uh, the Texas order, of course, which is a, you know, pure product order. Uh, but, um, uh, we see a strong opportunity in the US to, uh, as I've talked about before, retrofit also existing LINACs. Uh, but we also see indications that customers are able to make faster decisions on OpEx investments than on CapEx products. Uh, and it has been favorable for our service business. Uh, but in the short term, it might impact our product business. And our assessment is that this is connected to the uncertainty around trade and tariffs.

Christian Lee
21:55 - 22:03

And I. And I. And I. And my second question, did you have any negative impact on the results from the tariff situation?

Linda Frölén
22:05 - 22:07

Uh, not in this quarter, no.

Christian Lee
22:10 - 22:14

Do you expect any negative impact in the third quarter?

Linda Frölén
22:16 - 22:45

Uh, as you all know, these decisions are put on hold for now. Uh, our current assessment is that it's only the hardware that will be affected. And our general terms and conditions allow us to pass on the cost of tariffs to the customer. And, uh, in the near term, we don't see any major effects of the tariffs.

Christian Lee
22:47 - 23:01

Okay. That's clear. Thank you very much. And my last question, given that organic sales decreased by 13% in the second quarter, do you feel confident about reaching your target of 10% growth for the full year?

Cecilia de Leeuw
23:03 - 23:29

So just to remind you of our financial targets, it's actually over the mid-term. Uh, so it's in the mid-term, uh, so we will continue working and, uh, looking at the order intake, uh, which is the first important step to get revenue. Uh, and just as a reminder, it's typically 6 to 8 months from order to delivery. That's a good step in the right direction.

Christian Lee
23:33 - 23:35

Okay. Perfect. Thank you very much.

Operator
23:41 - 24:01

As a reminder, if you wish to ask a question, please dial the Pound Key on your telephone keypad or click the raised hand symbol on the webcast. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Cecilia de Leeuw
24:11 - 24:35

Thank you all for attending our Q2 presentation. And I mentioned earlier that we are on a journey, and this is vital because we are here to increase safety and efficiency in cancer care. And this is important not only for patients and clinics, but also for shareholders. And with that, I want to thank you and wish you a nice summer.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…